EMA accepts ViroPharma's filing of Cinryze for HAE
This article was originally published in Scrip
Executive Summary
The EU's EMA has accepted ViroPharma's filing of Cinryze (C1 inhibitor (human)) for the acute treatment and prophylaxis against hereditary angioedema (HAE), which was submitted through the centralised procedure earlier this month.